HR 7486, the Protecting Hospitals from Disaster Act of 2026, requires Quality Improvement Organizations (QIOs) to help hospitals and specific healthcare facilities prepare for and respond to extreme weather events. The bill allocates $50 million from Medicare funds in fiscal year 2026 to support this QIO assistance. It directly affects hospitals, psychiatric hospitals, skilled nursing facilities, critical access hospitals, long-term care hospitals, rural emergency hospitals, and inpatient rehabilitation facilities. The key mechanism is mandating QIOs to provide preparedness support to these facilities using the dedicated funding.
S 2628, the Catastrophic Specialty Hospital Act of 2025, creates a new Medicare payment designation for long-term care hospitals specializing in spinal cord injury and acquired brain injury rehabilitation. Hospitals meeting strict criteria - such as having at least 80% of discharges for these conditions over three years, 175+ annual discharges per condition, 30% out-of-state patients, and research commitments - will receive special Medicare payments instead of standard rates. This directly affects qualifying specialized hospitals, changing how Medicare reimburses them for care. The designation lasts three years and requires annual renewal based on continued compliance with the criteria.
Medicaid VBPs for Patients Act or the MVP Act This bill provides statutory authority for regulations that allow for the use of varying best price points under value-based purchasing arrangements for purposes of the Medicaid Drug Rebate Program. ( Value-based purchasing arrangements refer to arrangements in which the price of a drug is linked to clinical outcomes; such arrangements are particularly used for new high-cost treatments, such as gene therapies.) The Government Accountability Office must study the impact of value-based purchasing arrangements on federal health care programs, including with respect to the bill's changes. Additionally, the bill (1) exempts sales of drugs that are made under value-based purchasing arrangements from calculations of the manufacturer average sales price for purposes of payments under Medicare medical services, if the manufacturer reports multiple best prices under Medicaid in accordance with the bill's changes; and (2) requires the Centers for Medicare & Medicaid Services to issue guidance on how state Medicaid programs may cover drugs in inpatient settings via value-based purchasing arrangements.
The BRAIN Act creates new research initiatives to improve brain tumor treatment and care. It establishes a searchable database of NIH-funded brain tumor biospecimens, funds a Glioblastoma Therapeutics Network with $50 million annually, and supports cellular immunotherapy research with $10 million annually. The bill also mandates a national awareness campaign about clinical trials and biomarker testing, and funds pilot programs to improve care coordination for brain tumor survivors. These provisions directly affect over 1 million Americans living with brain tumors and aim to improve research coordination, treatment options, and quality of life through concrete funding and policy changes.
This bill allows groups of small businesses or self-employed individuals to form a single health plan that treats all members as one employer for coverage purposes. It directly affects small business associations and self-employed people who can join such groups to access pooled health coverage, provided they meet specific requirements (e.g., 51+ total employees, 2+ years in existence, no health-based discrimination). Key mechanisms include permitting modified community rating for premiums (based on pooled claims) while prohibiting health status-related discrimination in enrollment, premiums, or pre-existing condition coverage. The plan remains subject to federal ERISA rules, and self-employed members must meet defined criteria to participate as both employers and employees.
HR 1417 establishes a new program within the U.S. Department of Agriculture to provide tailored technical assistance to rural health care facilities. The program directly supports facilities like hospitals, clinics, and health centers in rural areas by helping them identify operational needs, improve financial management, and access USDA loan and grant programs. Key provisions include prioritizing facilities in medically underserved areas or facing financial vulnerability, with a $2 million annual funding limit for fiscal years 2026-2030. The program requires annual reports on outcomes and effectiveness to Congress, focusing on preventing facility closures and strengthening rural health care delivery.
The ETHIC Act (S 2276) limits patent holders from asserting multiple related patents against generic drug and biosimilar manufacturers. It restricts claims to one patent per "Patent Group" (defined as commonly owned patents linked through specific disclaimer filings) in infringement lawsuits involving drug/biosimilar applicants. This applies to cases related to FDA applications under 505(b)(2), 505(j), or 351(k) pathways for new drug approvals. The law aims to reduce legal barriers for competition by preventing patent thickets from delaying generic/biosimilar market entry.
HCONRES 53 is a symbolic resolution expressing the House of Representatives' support for recognizing September 26, 2025, as "World Contraception Day" and outlining policy principles for improving contraception access. It calls for expanding universal, affordable access to contraception - including over-the-counter options - and addressing disparities affecting Black, Indigenous, and other marginalized communities facing barriers like "contraceptive deserts" and discrimination. The resolution urges federal action to support comprehensive sex education, eliminate insurance cost-sharing for contraception, train healthcare providers on contraceptive care, and fund programs like Title X. It does not create new laws but affirms congressional support for policies that ensure reproductive autonomy and reduce preventable health issues linked to limited access.
This bill creates the Office of Climate Change and Health Equity within the Department of Health and Human Services to coordinate federal efforts addressing climate change's health impacts, with special focus on environmental justice communities and medically underserved populations. It requires the development of a National Strategic Action Plan within one year of enactment, to be updated annually, that identifies climate-related health risks and outlines strategies to protect vulnerable communities. The bill also establishes a science advisory board of experts and authorizes $10 million annually for the Office through fiscal year 2031 to support activities including tracking climate health risks, developing preparedness plans, and reducing greenhouse gas emissions in the health sector.
This bill prioritizes states that have never received a Department of Veterans Affairs (VA) suicide prevention grant. It requires the VA Secretary to give all eligible applicants in such states a scoring preference during grant evaluations until at least one grant is awarded there. The law directly affects veterans in states without existing VA suicide prevention grants by ensuring these states receive fair consideration for funding. Key mechanisms include prioritizing entities in states with prior unawarded applications and applying a scoring preference for all applicants in states with no prior grants. This aims to expand access to mental health support for veterans nationwide.